Indivior (NASDAQ:INDV) Given New $13.00 Price Target at Piper Sandler

Indivior (NASDAQ:INDV) had its target price lowered by Piper Sandler from $16.00 to $13.00 in a report released on Thursday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other brokerages have also recently commented on INDV. Rodman & Renshaw started coverage on Indivior in a report on Tuesday, January 28th. They set a “buy” rating and a $16.00 target price on the stock. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a report on Tuesday, January 28th.

Indivior Price Performance

Indivior stock opened at $9.70 on Thursday. The stock has a fifty day moving average price of $10.91 and a two-hundred day moving average price of $10.59. Indivior has a 52-week low of $7.33 and a 52-week high of $22.53. The firm has a market capitalization of $1.34 billion, a P/E ratio of -27.71 and a beta of 0.82.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.32. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The firm had revenue of $298.00 million during the quarter, compared to analyst estimates of $262.35 million. On average, equities research analysts predict that Indivior will post 1.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new position in Indivior in the fourth quarter valued at approximately $36,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Indivior during the 4th quarter valued at $56,000. Lazard Asset Management LLC acquired a new position in shares of Indivior in the 4th quarter valued at $57,000. Stifel Financial Corp acquired a new position in shares of Indivior in the 3rd quarter valued at $100,000. Finally, Melqart Asset Management UK Ltd acquired a new position in shares of Indivior in the 3rd quarter valued at $132,000. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.